Stay updated with breaking news from Partial Responses. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Favorable preliminary safety profile of NVL-520 suggests potential for a highly ROS1-selective, TRK sparing design, with no dose-limiting toxicities,...
Favorable preliminary safety profile of NVL-520 suggests potential for a highly ROS1-selective, TRK sparing design, with no dose-limiting toxicities,...
(0) First pivotal study to compare Peptide Receptor Radionuclide Therapy (PRRT) in patients with Grade 1 and 2 gastroenteropancreatic neuroendocrine tumors (GEP-NETs) with approved standard of care ITM AG today announced the presentation of a trial-in-progress poster highlighting its ongoing Phase III trial COMPETE with n.c.a. 177Lu-Edotreotide in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021. The poster will be presented in video format as part of the Phase III trials in progress p...
Press release content from Globe Newswire. The AP news staff was not involved in its creation. Zentalis Pharmaceuticals Announces Promising Initial Data Presented in a Late-Breaking Session ... ZENTALIS PHARMACEUTICALSApril 10, 2021 GMT ZN-c3 demonstrated single agent activity, generating Exceptional Responses in a range of heavily pre-treated solid tumors ZN-c3 was safe and well-tolerated Identified recommended Phase 2 dose for ZN-c3 to be 300 mg QD with continuous dosing Announces plan to start Phase 1/2 osteosarcoma trial in Q3 2021 Company to host webcast event with key opinion leaders on...